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1. Introduction 
It is now clear that lipid phosphorylation and hydrolysis 
plays a pivotal role in the transmission of extracellular stimuli 
across the cytoplasm [1,2]. Consequently, great effort has been 
applied to characterize the enzymes responsible for these sig-
nalling events [3-5]. This article will present an overview of 
one family of lipid kinases; namely the phosphomositide 3-
kinases (PI3-kinases) which are found in species ranging from 
slime mold to man and catalyse the addition of phosphate to 
the 3' position on the inositol ring of phosphoinositides. 
We offer a classification of the rapidly expanding number of 
PI3-kinase family members based principally on their struc-
ture and discuss our understanding of their regulation and 
downstream targets. In this way we hope to provide a frame-
work within which the nomenclature of PI3-kinase family 
members can be standardised. 
2. The early years 
In the mid 1980's immunoprecipitates of pp60v~src, polyo-
ma middle T/pp60c~src complexes and p68v~ros, the transform-
ing protein of the avian sarcoma virus UR2 were found to 
contain a novel lipid kinase activity which phosphorylated 
phosphatidylinositol (Ptdlns) on the 3' position of its inositol 
ring (reviewed in [6]). A similar PI3-kinase activity was later 
found associated with activated platelet derived growth factor 
receptors where PtdIns(4)P and PtdIns(4,5)P2 were used as 
substrate [7]. None of these 3' phosphorylated lipids served 
as substrates for phospholipase C or D suggesting that they 
could fulfil an independent second messenger function [8]. 
Such findings stimulated great excitement since they suggested 
that pharmaceutical attenuation of this novel lipid kinase ac-
tivity could inhibit mitogenesis and consequently control on-
cogenesis. Numerous studies have subsequently demonstrated 
a much broader role for this lipid kinase and its products in 
cell physiology/ pathophysiology [4]. 
At the time it was unclear as to how one enzyme could 
mediate such a multiplicity of functions. A clue as to how 
such specificity could be achieved was however, already evi-
dent from those early experiments. Ligand stimulation acutely 
elevated levels of both PtdIns(3,4)P2 and PtdIns(3,4,5)P3 com-
pared to resting cells (reviewed in [9]). In contrast, the con-
stitutively elevated level of PtdIns(3)P remained largely unal-
tered. Such results suggested that PtdIns(3)P plays a more 
central, metabolic role whilst the more highly phosphorylated 
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phosphoinositides function as the ligand responsive second 
messengers. 
3. Characterization of the enzyme 
PI3-kinase was first identified as an 85-kDa phosphoprotein 
whose appearance correlated with a PI3-kinase activity in im-
munoprecipitates from a number of polyoma middleT mu-
tants [10]. These studies facilitated the purification and sub-
sequent cloning of a heterodimeric complex comprised of an 
85-kDa adaptor (p85) and a 110-kDa catalytic subunit (pi 10) 
[11,12]. Cloning of the PI3-kinase catalytic subunit revealed a 
sequence similarity within its catalytic domain to yeast 
Vps34p a protein involved in vesicular trafficking later shown 
to also possess PI3-kinase activity [13]. Such sequence align-
ment within the kinase domains allowed the use of polymerase 
chain reaction based strategies to isolate and characterize nov-
el PI3-kinase family members. Over the last five years we have 
witnessed an explosion in the number of PI3-kinase catalytic 
and regulatory subunits described in the literature [5]. Con-
sequently, the wealth of information generated has proved 
confusing for many unfamiliar with this area of study. For-
tunately, as we learn more about this family of signalling 
molecules, a basis for their classification has emerged. 
4. Three classes of PI3-kinase 
The classification of PI3-kinase family members we propose 
is based on their structure and probable mechanism of regu-
lation. In mammals, we currently know of 7 forms of the 
catalytic subunit and 5 forms of associated binding partner / 
adaptor subunit. These catalytic and adaptor subunits can be 
divided into three main classes (Fig. 1): 
4.1. Class I PI3-kinases 
These enzymes all form a heterodimeric complex with an 
adaptor protein which renders them responsive to ligand stim-
ulation. In vitro, they can utilise Ptdlns, PtdIns(4)P and 
PtdIns(4,5)P2 as substrate but in the cell, they appear to pref-
erentially phosphorylate PtdIns(4,5)P2 [9]. The reason for this 
disparity is presently unclear although it is most likely to be a 
consequence of substrate presentation (see below). 
This class of PI3-kinase is subdivided based on the form of 
adaptor subunit with which the catalytic subunit associates. 
4.2. Class I A PI3'-kinases 
These form a heterodimeric complex consisting of a 110-
120-kDa catalytic subunit and an adaptor protein which con-
tains two src homology 2 (SH2) domains. Mammalian class 
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Fig. 1. The classification of PI3-kinase family members. The assignment of catalytic subunits to a particular class is based on sequence homol-
ogy within the catalytic domain [5]. To date, PI3K-C2a is the only class II member which has been shown to phosphorylate PtdIns(4,5)P2. 
IA catalytic subunits include pi 10a, pllOp and pi 108 [14-16]. 
They all contain a domain which binds p85, a region for ras 
association [17] a PI kinase (PIK) domain and a C-terminal 
catalytic domain. The PIK domain is a region conserved 
amongst all PI3 and PI4-kinases and although its role is pres-
ently unclear, it is likely to be involved in substrate presenta-
tion [18]. Although both pi 10a and pllOp demonstrate a 
ubiquitous tissue distribution, the expression of the recently 
identified pi 108 is restricted to leukocytes thereby implying a 
specificity of function [16]. All members of this class bind the 
p85 adaptor subunit through which they can be recruited to 
receptor signalling complexes upon activation of tyrosine kin-
ase activity [19]. 
The first adaptors to be identified for the class IA catalytic 
subunits were p85a and p85|3 [20]. Both proteins contain two 
SH2 domains separated by an inter SH2 domain through 
which the adaptor interacts with pi 10 [21]. At the N terminus 
there is a src homology 3 (SH3) domain [22] and a breakpoint 
cluster region homology (BH) domain which has homology 
with the GAP (GTPase activating protein) domain of the 
BCR gene product [23] Although BH domains have been 
identified in a number of proteins which display GAP activity 
towards the Rho family GTPases, no equivalent biochemical 
activity has, as yet, been found for the BH domain of p85. 
Two proline rich regions flank the BH domain raising the 
possibility that the p85 SH3 domain may interact with either 
of these polyproline motifs to confer an allosteric change in 
the adaptor [24]. Such conformational change, perhaps upon 
receptor binding, might modulate the kinase activity of the 
catalytic subunit. 
A number of smaller adaptor proteins have been identified 
which also bind the class IA catalytic subunits. These mole-
cules are homologous to p85 but lack its SH3 domain, one of 
the two proline rich regions and the BH domain. Although 
some are generated by alternate splicing of the p85a gene, 
mouse p55PIK and its bovine homologue p55y (p85y) are en-
coded by independent genes [25,26]. The significance of such 
adaptor diversity is unclear since they do not display selectiv-
ity in binding the catalytic subunit. Since they show a tissue 
specific distribution, it is possible that such structural modifi-
cations may be of regulatory significance. Nature has thus 
provided a number of deletion mutants with which compara-
tive biochemical analysis may be performed to reveal the func-
tional role of the p85 SH3 and BH domains. 
In addition to lipid kinase activity, class IA PI3-kinases also 
possess an intrinsic ser/thr protein kinase activity [27,28]. This 
serves to phosphorylate the associated adaptor within the in-
ter-SH2 domain of p85 in the case of pi 10a and pllOp [28], 
or facilitates autophosphorylation as with pllOy [16]. The in-
sulin receptor protein tyrosine kinase substrate IRS-1 is the 
only exogenous protein reportedly phosphorylated by pi 10a 
[29]. Phosphorylation of p85a Ser 608 which is located within 
its inter-SH2 domain has been proposed to regulate the lipid 
kinase activity of the catalytic subunit [28]. It may be of some 
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functional significance however that some of the smaller adap-
tor subunits lack a residue equivalent to Ser 608 in this region. 
4.3. Class /B PI3-kinases 
Studies in platelets and neutrophils, have identified a form 
of PI3-kinase acting downstream of receptors which signal 
through heterotrimetric G-proteins [30,31]. Fractionation of 
neutrophil and U937 cell lysates resulted in the isolation of 
a PtdIns(4,5)P2 selective kinase activity which was chromato-
graphically distinct from the class IA enzymes [32]. This PI3-
kinase complex was activated by heterodimeric GTPase py 
subunits, possessed a native molecular mass of 220 kDa and 
did not contain a p85 like adaptor subunit. The cloning of 
pllOy defined a G-protein activated PI3-kinase catalytic sub-
unit but its associated adaptor remained elusive [33]. With an 
effort not seen in the PI3-kinase field for many years, Stephens 
et al recently purified and cloned a porcine protein of 120 
kDa, highly related to pllOy and a 97-kDa adaptor termed 
plOl based on its electrophoretic mobility [34]. Binding of 
pllOy to the plOl adaptor rendered it considerably more sen-
sitive to activation by Py subunit. Although the plOl/pllOy 
complex cannot be stimulated by tyrosine phosphorylated 
peptides, pllOy does contain a functional ras binding domain 
[35,36]. 
5. Class II PI3-kinases 
These catalytic subunits are the largest (170-220 kDa) and 
the most recently identified form of PI3-kinase. Distinctively, 
they all contain a C-terminal C2 domain (Fig. 1). The C2 
domain was originally defined as the second of four conserved 
regions within mammalian protein kinase C (PKC) where it 
conferred a Ca2+ sensitive phospholipid binding [37]. This 
property is not however, displayed by all C2 domains since 
only the first (C2A) but not the second (C2B) of two C2 
domains within the synaptic vesicle protein synaptotagmin 
behaves in this manner [38]. In contrast, the synaptotagmin 
C2B domain mediates both a Ca2+-dependent dimerization 
[39] and a Ca2+ independent association with the clathrin-
AP2 complex [40]. 
The description of Drosophila PI3K 68_D [41] was followed 
shortly by the two murine sequences m-cpk and pl70 [42,43], 
human PI3K-C2a [44] and an independent confirmation of 
the 68_D sequence (cpk) [42]. The two mouse proteins are 
likely to be products of the same gene and are the murine 
homologue of human PI3K-C2a. When lipid substrate specif-
icity was examined, both PI3K_68D and pl70 were shown to 
phosphorylate only Ptdlns and PtdIns(4)P [41,43]. This of-
fered the attractive proposition that structural differences be-
tween members of each class of PI3-kinase might reflect the 
type of 3' phosphorylated phosphoinositide they produce. 
This hypothesis was revised when the lipid substrate specificity 
of human PI3K-C2a was determined. In the presence of 
PtdSer, PI3K-C2a also phosphorylated PtdIns(4,5)P2 [44]. 
Although it is unclear whether this is a property displayed 
by other class II members it demonstrates the importance of 
lipid presentation during the assignment of in vitro activity 
and may explain the discrepancy between the in vitro findings 
and apparent in vivo specificity of pi 10a. Additionally, PI3K-
C2oc and murine pi70, but not Drosophila 68_D/cpk, are re-
fractory to both wortmannin and LY294002, two widely used 
inhibitors of PI3 kinase activity. 
Like the synaptotagmin C2B domain, the PI3K 68_D C2 
domain binds phospholipids in a Ca2+-independent manner 
but its role within the class II PI3-kinase family members 
remains unclear [41]. Currently there is no indication that 
the C2 domain confers a Ca2+ sensitivity to this class of en-
zyme. The recent identification of a second, human class II 
PI3-kinase suggests the potential for differential regulation of 
enzyme activity as observed amongst the class I members [45]. 
6. Class III PI3-kinases 
Vps34p and its human homologue Ptdlns 3-kinase can only 
phosphorylate Ptdlns [46]. Since Vps34p is the only PI3-kin-
ase present in yeast, members of this class are considered to be 
the primordial form of PI3-kinase. Consequently, yeast pro-
vides an ideal model system within which to study the conse-
quence of PtdIns(3)P production. Mutational analysis has 
identified a role for this lipid kinase in vesicular trafficking, 
osmoregulation and enodocytosis (reviewed in [47]). Vps34p 
binds the ser/thr kinase Vpsl5p which recruits it to mem-
branes and activates lipid kinase activity. Similarly, Ptdlns 
3-kinase binds pi50 a homologue of Vpsl5p [48]. We know 
little about the functional domains of Ptdlns 3 kinase, aside 
from its catalytic and PIK domains and an as yet uncharac-
terized motif which binds pi50. 
In contrast, the study of the Vpsl5/pl50 protein is more 
advanced. It has an N-terminal myristylation site, a ser/thr 
kinase domain, a series a HEAT repeats [49] and C-terminal 
WD motifs [50]. Although these domains provide a focus for 
study, their significance is presently unclear. Our studies in-
dicate that mammalian pi50 serves to target Ptdlns 3-kinase 
to a perinuclear localization and using the yeast Vps34p/ 
Vpsl5p model as a paradigm it is likely that the human ho-
mologues will fulfil an equivalent biological role in mediating 
vesicular trafficking. The possibility that PtdIns(3,5)P2 medi-
ates the downstream effects of the class III PI3-kinases re-
quires further investigation [51]. 
7. PI3-kinase related proteins 
These are large proteins ( > 270 kDa) which contain a re-
gion homologous to the PI3-kinase catalytic domain. They 
include the ataxia telangiectesia-mutated gene product, the 
targets of rapamycin (TOR) and the DNA-dependent protein 
kinase (reviewed in [52]). To date, none of these proteins have 
been found to display lipid kinase activity. 
8. Regulation of PI3-kinase activity 
Most of what we know about PI3-kinase activation and 
regulation has been gained from the study of the class I mol-
ecules. The reason for this is principally chronological, never-
theless, a greater understanding of class II and III enzymes is 
being generated through their identification and the develop-
ment of appropriate reagents. Such studies will allow us to 
better understand how the different family members can fulfil 
their physiological function in a concerted manner. 
Class I PI3-kinases have been demonstrated to play a role 
in almost every receptor mediated signalling event. Ligand 
stimulation results in either the activation of intrinsic receptor 
tyrosine kinase activity, the recruitment of an associated ty-
rosine kinase or the activation of heterotrimeric G-proteins. 
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When tyrosine residues become phosphorylated and are pre-
sented within a pTyr-X-X-Met consensus sequence they serve 
as docking sites for the class IA adaptor subunit SH2 domains 
[53]. Phosphopeptide binding to p85 SH2 domains results in 
an activation of lipid kinase activity [35]. Translocation to the 
plasma membrane not only brings the catalytic subunit into 
close proximity with its lipid substrate but it also facilitates 
the interaction with GTP bound ras thereby increasing PI3-
kinase activity [17]. This places the class IA PI3-kinases on a 
pathway parallel to the raf ser/thr kinase [54]. The degree to 
which PI3-kinase activity is dependent upon ras is currently 
unclear [55]. 
Little is known about how heterotrimeric G-proteins acti-
vate the class IB PI3-kinase. Whilst G|3y can directly stimulate 
pllOy lipid kinase activity this stimulation is considerably en-
hanced in the presence of the pi01 adaptor [34]. 
9. Downstream targets of PI3 kinase 
The hunt to identify major downstream targets of PI3-kin-
ase has been fraught with difficulty. The identification of lipid 
binding domains such as the pleckstrin homology (PH) do-
main [56] and the C2 domain supports the view that down-
stream targets are likely to be proteins. Some have even con-
sidered if the protein kinase activity intrinsic to the catalytic 
subunit could mediate its downstream response [57]. Potential 
downstream targets of PI3-kinase activity include: 
9.1. p70S6 kinase 
p70S6 kinase phosphorylates the 40S ribosomal protein S6 
in response to mitogenic stimuli and plays a key role in Gl to 
S phase transition through the cell cycle [58]. Although acti-
vation of p70se kinase is achieved by a ser/thr protein kinase 
activity independent of the raf/MAPK pathway [59], evidence 
suggest that p70S6 kinase is an important downstream target 
of PI3-kinase. Overexpression of receptor mutants which fail 
to bind the p85 adaptor and the use of PI3 kinase inhibitors 
both block ligand induced activation of p70S6 kinase [60]. 
Furthermore, constitutive PI3-kinase activity results in the 
phosphorylation of p70S6 kinase and antisera which target 
p70S6 kinase block the mitogenic activity of PI3-kinase 
[61,62]. Mammalian TOR is another important regulator of 
p70S6 kinase but neither pi 10 nor mammalian TOR phos-
phorylate p70S6 kinase directly. Since N-terminal truncations 
of p70se kinase render it sensitive to wortmannin but not 
rapamycin, it is thought that PI3-kinase and mammalian 
TOR activate p70S6 kinase independently [63,64]. 
9.2. Akt kinase 
The Akt ser/thr kinase is the cellular homologue of the 
retroviral oncogene v-akt and is activated upon ligand stim-
ulation of receptor tyrosine kinases [65,66]. The Akt protein 
contains an N-terminal PH domain [56] in addition to the 
protein kinase domain. As with p70S6 kinase, expression of 
receptor mutants which do not bind p85 and inhibitors of PI3 
kinase block ligand induced Akt activation [66,67]. Although 
a direct and specific activation of Akt kinase activity by 
PI(3,4)P2 has been reported [68,69] the significance of these 
findings has been questioned by the isolation of an Akt kinase 
termed PDK1 [70]. PDK1 is activated by both PtdIns(3,4)P2 
and PtdIns(3,4,5)P3. Downstream of Akt lies GSK3, a con-
stitutively active protein kinase whose activity is attenuated by 
Akt [71]. GSK3 appears to act as a negative inhibitor of both 
transcription and translation factors such as c-jun and eIF-2B 
in addition to metabolic enzymes such as glycogen synthase 
[72]. Consequently, activation of Akt by PI3-kinase leads to 
the phosphorylation and inhibition of GSK3 which, in turn, 
activates a number of key regulatory proteins. 
9.3. Rac 
The ras related GTP binding protein rac has been suggested 
as a downstream target of PI3-kinase [73,74]. Rac is thought 
to activate the JNK/stress activated protein kinase which 
phosphorylates c-jun [75]. 
9.4. Protein kinase C and related kinases 
Calcium-independent isoforms of protein kinase C and pro-
tein kinase C related kinases have been found to be activated 
in vitro by 3' phosphoinositides [76,77]. A similar mechanism 
has been proposed to act in whole cells [78]. Unfortunately, 
the specificity of these effects remains a contentious issue. 
10. Conclusion 
The pace at which novel PI3-kinase family members have 
been identified has surpassed the rate at which we have learnt 
about their biology. We are currently on the threshold of 
completing our catalogue of the players and through structur-
al analysis we will soon learn much about their mechanisms of 
activation. By comparison, our understanding of how the ac-
tivity of different family members is orchestrated within the 
cell and how the 3' phosphorylated lipids achieve their spec-
trum of cellular effects remains rudimentary. The challenge 
ahead is to answer such questions and learn how best to ex-
ploit this knowledge for therapeutic benefit. 
11. Apologies 
We apologise to the authors of original papers whose refer-
ence could not be cited due to space limitations. 
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